Clinical Trial Information
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy and Safety Of Giredestrant Plus Everolimus Compared with The Physician’s Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer- Category: Breast
- Status: Active
- Starts: Jun 27, 2023
- Stage: III
- Trial Number: ML43171
Principal Investigator: Jose Galeas, MD
Research Nurse: Wendy Blount, RN, MSN
Description of Trial:
This study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician’s choice of endocrine therapy plus everolimus in patients with estrogen-receptor positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
NCT05306340
Please click here for additional information about this study.